NasdaqGS:TEMLife Sciences
Assessing Tempus AI (TEM) Valuation After New Lung Cancer Screening Partnership
Why Tempus AI’s new lung cancer screening partnership matters
Tempus AI (TEM) just announced a collaboration with Median Technologies to bring FDA cleared eyonis LCS lung cancer screening software into the Tempus Pixel platform, putting more focus on early detection and clinical workflows.
See our latest analysis for Tempus AI.
The Median partnership arrives after a choppy stretch for Tempus AI, with a 1 day share price return of 2.30% to US$51.95, following a 30 day share price return...